Constructing an efficient and safe producer strain is a prerequisite for biosynthetic production of 2’-fucosyllactose. The number and technical content of recent patents on 2’-fucosyllactose biosynthesis applied for in China are reviewed in this paper, indicating that over 80 percent of the patents focused on the construction of recombinant strains by optimizing the metabolic pathways, overexpressing 2’-fucosyllactose biosynthesis-related enzyme genes, and developing more safe and efficient host strains. However, after a review of China’s patented technologies in this regard, we found that research on the biosynthetic production of 2’-fucosyllactose in a pilot scale or above is weak, and there is a lacuna in utility and industrially oriented patented technologies, which will bottleneck the 2’-fucosyllactose biosynthesis industry in China.